Recent advances in mineralocorticoid receptor antagonists for heart failure with preserved ejection fraction: focus on finerenone in the era of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. [PDF]
Front PharmacolWang TY, Zhang L, Wang HY, Jiang FF.
europepmc +1 more source
Aldosterone: From Essential Tubular Regulator to Pathological Driver-Physiology, Disease, and Therapeutic Advances. [PDF]
Int J Mol SciStrizzi CT +3 more
europepmc +1 more source
Spironolactone in end stage renal disease: A story of under'ACHIEVE'ment. [PDF]
J Bras NefrolMathew GG.
europepmc +1 more source
Mineralocorticoid receptor antagonists in heart failure: a systematic review and meta-analysis. [PDF]
Front Cardiovasc MedZhang Y +10 more
europepmc +1 more source
An individual treatment effect approach to predict response to mineralocorticoid receptor antagonists in patients with heart failure and reduced ejection fraction. [PDF]
Eur J Heart FailKobayashi M +9 more
europepmc +1 more source
Female sex hormones do not drive the sex-specific mechanisms of obesity-related hypertension. [PDF]
Am J Physiol Heart Circ PhysiolBarris CT +8 more
europepmc +1 more source
Cardiac response to chronic restraint stress involves mineralocorticoid receptors in male Sprague-Dawley rats. [PDF]
Physiol RepSztechman D +4 more
europepmc +1 more source
Aldosterone Synthase Deficiency Type I in a Neonate: Diagnostic, Genetic, and Therapeutic Insights From a Novel CYP11B2 Variant. [PDF]
CureusKhalifa HM +4 more
europepmc +1 more source
Favorable outcomes of SGLT2 inhibitor use in pacemaker recipients: a population-based study. [PDF]
Cardiovasc DiabetolAvidan Y +6 more
europepmc +1 more source